In light of H5N1 outbreak, U.S. in talks with mRNA vaccine makers on bird flu
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. Wall Street had a big reaction to H5N1 bird flu news yesterday. Was it warranted? We’ll discuss that today.
